WHO approves first malaria treatment for newborns

On April 24, 2026, the World Health Organization (WHO) announced a historic milestone in global health by approving Coartem Baby, the first malaria treatment specifically designed for newborns and infants weighing between 2 and 5 kilograms.

Historically, doctors had to adapt adult or older-child dosages for these vulnerable patients, which often led to dangerous side effects.

This new, precision-formulated medication addresses a critical gap for the 30 million babies born annually in malaria-endemic areas.

Developed by Novartis and the Medicines for Malaria Venture, this treatment is expected to be distributed on a not-for-profit basis to ensure broad access.

This advancement is particularly timely, as children under five years old account for up to 75% of global malaria-related deaths.

While Sub-Saharan Africa remains the region hardest hit by the disease, global efforts are currently challenged by rising drug resistance and declining international support.